Inflammatory Myofibroblastic Tumour Clinical Trial
Official title:
Treatment With Crizotinib Single Patient Expanded Access IND 134375
| NCT number | NCT03085186 |
| Other study ID # | PRO17030033 |
| Secondary ID | |
| Status | No longer available |
| Phase | N/A |
| First received | March 14, 2017 |
| Last updated | August 28, 2017 |
| Verified date | August 2017 |
| Source | University of Pittsburgh |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Expanded Access |
Two year old male with a new diagnosis of Inflammatory Myofibroblastic Tumour. The patient
presented with 2 months of intermittent fever and 1-2 weeks of abdominal distention and
constipation. An abdominal mass was palpable on exam and US concerning was for neoplasm of
abdomen.
Treatment with Crizotinib will be utilized to reduce the size of the lesion and create more
optimal tissue plains between vital structures prior to attempted surgical resection would
greatly reduce potential morbidity for this patient.
| Status | No longer available |
| Enrollment | 0 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | |
| Gender | Male |
| Age group | 2 Years to 2 Years |
| Eligibility |
Inclusion Criteria: - This treatment plan is intended for the use of Crizotinib in the treatment of a single patient with Inflammatory Myofibroblastic Tumour Exclusion Criteria: - Not applicable as Expanded Access only includes one patient |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Jean M. Tersak, M.D. | Pfizer |